Drugs / Fast TIL
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07443020 | May 2026 → Mar 2033 expected | malignant mesothelioma, pleural neoplasm | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Recruiting | No outcome recorded |
| Phase 1 | NCT07192900 | Mar 2026 → Dec 2032 expected | malignant mesothelioma, pleural neoplasm | David Bartlett, MD | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fast TIL | “This research study aims to evaluate the safety and effectiveness of a novel immunotherapy, Fast TIL, an Adoptive Cellular Therapeutic (ACT), to fight cancer that has spread to...” NCT07443020 ↗1“This research study aims to evaluate the safety and effectiveness of a novel immunotherapy, Fast TIL, an Adoptive Cellular Therapeutic (ACT), to fight cancer that has spread to...” NCT07192900 ↗ |
| Modality | Cell therapy | “an Adoptive Cellular Therapeutic (ACT)” NCT07192900 ↗ |
| Route | Other | “Expanded cells will be delivered intrapleurally” NCT07192900 ↗ |